- Home
- CCJ vs BIIB Comparison
CCJ vs BIIB Comparison
Compare CCJ & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCJ
- BIIB
- Stock Information
- Founded
- CCJ 1987
- BIIB 1978
- Country
- CCJ Canada
- BIIB United States
- Employees
- CCJ N/A
- BIIB N/A
- Industry
- CCJ Other Metals and Minerals
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CCJ Basic Materials
- BIIB Health Care
- Exchange
- CCJ Nasdaq
- BIIB Nasdaq
- Market Cap
- CCJ 23.6B
- BIIB 25.1B
- IPO Year
- CCJ N/A
- BIIB 1991
- Fundamental
- Price
- CCJ $52.56
- BIIB $149.90
- Analyst Decision
- CCJ Strong Buy
- BIIB Buy
- Analyst Count
- CCJ 4
- BIIB 26
- Target Price
- CCJ $66.56
- BIIB $248.00
- AVG Volume (30 Days)
- CCJ 3.3M
- BIIB 1.5M
- Earning Date
- CCJ 02-20-2025
- BIIB 02-11-2025
- Dividend Yield
- CCJ 0.22%
- BIIB N/A
- EPS Growth
- CCJ N/A
- BIIB 10.05
- EPS
- CCJ 0.19
- BIIB 11.06
- Revenue
- CCJ $2,069,888,595.00
- BIIB $9,607,500,000.00
- Revenue This Year
- CCJ $17.28
- BIIB N/A
- Revenue Next Year
- CCJ $8.80
- BIIB N/A
- P/E Ratio
- CCJ $272.88
- BIIB $13.55
- Revenue Growth
- CCJ 23.31
- BIIB N/A
- 52 Week Low
- CCJ $35.43
- BIIB $145.07
- 52 Week High
- CCJ $62.55
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- CCJ 40.50
- BIIB 35.04
- Support Level
- CCJ $51.60
- BIIB $145.07
- Resistance Level
- CCJ $53.42
- BIIB $149.92
- Average True Range (ATR)
- CCJ 1.96
- BIIB 3.71
- MACD
- CCJ -0.63
- BIIB 0.26
- Stochastic Oscillator
- CCJ 9.38
- BIIB 30.65
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.